Literature DB >> 16480037

Helix-loop-helix proteins in lymphocyte lineage determination.

B L Kee1.   

Abstract

The cells of the lymphoid system develop from multipotent hematopoietic stem cells through a series of intermediate progenitors with progressively restricted developmental options. Commitment to a given lymphoid lineage appears to be controlled by numerous transcriptional regulatory proteins that activate lineage-specific gene expression programs and extinguish expression of lineage-inappropriate genes. In this review I discuss the function of transcription factors belonging to the helix-loop-helix protein family in the control of lymphoid cell fate decisions. A model of lymphocyte lineage determination based on the antagonistic activity of transcriptional activating and repressing helix-loop-helix proteins is presented.

Mesh:

Substances:

Year:  2005        PMID: 16480037     DOI: 10.1007/3-540-26363-2_2

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  5 in total

Review 1.  Multiple hats for natural killers.

Authors:  Kevin Ramirez; Barbara L Kee
Journal:  Curr Opin Immunol       Date:  2010-03-23       Impact factor: 7.486

Review 2.  E and ID proteins branch out.

Authors:  Barbara L Kee
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

Review 3.  Competition and collaboration: GATA-3, PU.1, and Notch signaling in early T-cell fate determination.

Authors:  Ellen V Rothenberg; Deirdre D Scripture-Adams
Journal:  Semin Immunol       Date:  2008-09-03       Impact factor: 11.130

4.  Cell lineages and the logic of proliferative control.

Authors:  Arthur D Lander; Kimberly K Gokoffski; Frederic Y M Wan; Qing Nie; Anne L Calof
Journal:  PLoS Biol       Date:  2009-01-20       Impact factor: 8.029

5.  Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity.

Authors:  Markus D Boos; Yoshifumi Yokota; Gerard Eberl; Barbara L Kee
Journal:  J Exp Med       Date:  2007-04-23       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.